Sertraline Associated with REM Sleep Behavior Disorder: A Case Report

Author(s): Seyed Mostafa Mansouripour*, Dharmendra Kumar

Journal Name: Current Psychopharmacology

Volume 8 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: REM sleep behavior disorder (RBD) is manifested by abnormal motor behavior with an endurance of tone during REM sleep. Studies suggest that patients taking Selective serotonin reuptake inhibitors (SSRIs) are at greater risk of developing REM sleep behavior disorder.

Case Presentation: We present a case of 39-year-old female with a past medical history of spinal cord injury from a gunshot wound 19 years ago resulting in paraplegia, posttraumatic stress disorder(PTSD), chronic pain, and chronic sleep problem. After sertraline started and up-titrated to 200 mg for her anxiety, she noticed worsening of her nighttime sleep behavior. Her mother also witnessed sleepwalking episode and doing things which the patient had no recollection in the morning, including trying to take a bath and eat from the refrigerator. On her follow-up appointment, her sertraline was discontinued altogether and she was started on Escitalopram 5 mg. She tolerated the medication well, it helped moderately with her anxiety and by the time of this case report (approximately 1 month) patient did not report any sleep-related behavior.

Conclusion: Since antidepressant medication is very commonly prescribed, it is important to be cautious of physiologic changes they may induce, even if the clinical significance of these changes is not fully elucidated. In addition, RBD may predict neurodegenerative disorders a couple of years earlier, so it may be used as an effective early marker of neurodegenerative diseases.

Keywords: Anti-depressant, anxiety, parasomnia, REM sleep behavior disorder (RBD), selective serotonin reuptake inhibitors (SSRI), sertraline.

[1]
Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010; 6(1): 85-95.
[2]
Winkelman JW, James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004; 27(2): 317-21.
[3]
Lam SP, Fong SYY, Ho CKW, Yu MWM, Wing YK. Parasomnia among psychiatric outpatients: a clinical, epidemiologic, cross-sectional study. J Clin Psychiatry 2008; 69(9): 1374-82.
[4]
Lee K, Baron K, Soca R, Attarian H. The prevalence and characteristics of REM sleep without atonia (RSWA) in patients taking antidepressants. J Clin Sleep Med 2016; 12(3): 351-5.
[5]
Zhang B, Hao Y, Jia F, et al. Sertraline and rapid eye movement sleep without atonia: an 8-week, open-label study of depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2013; 47: 85-92.
[6]
Tan L, Zhou J, Yang L, et al. Duloxetine-induced rapid eye movement sleep behavior disorder: a case report. BMC Psychiatry 2017; 17(1): 372.
[7]
Mahowald MW, Kim SW, O’Connor KA, Hurwitz TD. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated. Sleep 1992; 15(3): 226-35.
[8]
Parish JM. Violent dreaming and antidepressant drugs: or how paroxetine made me dream that I was fighting Saddam Hussein. J Clin Sleep Med 2007; 3(5): 529-31.
[9]
Williamsa R, Sandigob G. Venlafaxine-induced REM sleep behavioral disorder presenting as two fractures. Trauma Case Rep 2017; 11: 18-9.
[10]
Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72(15): 1296-300.
[11]
Postuma RB, Gagnon JF, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep 2013; 36(11): 1579-85.
[12]
Dores GM1. Bryant-Genevier M1, Perez-Vilar S1. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s adverse event reporting system, 2010-2017. JAMA Netw Open 2019; 2(8)e199249
[13]
Raschi E1. Girardi A2, Poluzzi E2, Forcesi E2, Menniti-Ippolito F3, Mazzanti G4, De Ponti F2. Adverse events to food supplements containing red yeast rice: comparative analysis of FAERS and CAERS reporting systems. Drug Saf 2018; 41(8): 745-52.
[14]
Tibau A1. Ocana A2, Anguera G1, Seruga B3, Templeton AJ4, Barnadas A1, Amir E5. Oncologic drugs advisory committee recommendations and approval of cancer drugs by the us food and drug administration. JAMA Oncol 2016; 2(6): 744-50.


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 2
Year: 2019
Page: [159 - 162]
Pages: 4
DOI: 10.2174/2211556008666190802101939

Article Metrics

PDF: 21
HTML: 4